BioCatalystWatch
AGENWorkspace / AGEN / OverviewCompany library
Price
Market cap
Next catalystNovember 2026 SITC presentationsbalstilimab-plus-botensilimab · Conference presentationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

CTLA-4 × PD-1

Upcoming / outlook

  • Timing and evidence

CTLA-4 × PD-1

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

CTLA-4 × PD-1

Upcoming / outlook

  • Timing and evidence

CTLA-4 × PD-1

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

AGEN1423

CD73 × TGFβ

PreINDP1P2P3FilingApproved
AGEN1571

ILT2

PreINDP1P2P3FilingApproved
AGEN1721

FAP × TGFβ

PreINDP1P2P3FilingApproved
INCAGN01876

GITR

PreINDP1P2P3FilingApproved
zalifrelimab + balstilimab + doxorubicin

CTLA-4

PreINDP1P2P3FilingApproved

Partner / License out

CD137

PreINDP1P2P3FilingApproved

CD137

PreINDP1P2P3FilingApproved

ILT4

PreINDP1P2P3FilingApproved

ILT4

PreINDP1P2P3FilingApproved

ILT4

PreINDP1P2P3FilingApproved

ILT4

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Approved / commercial

CTLA-4

balstilimab (BAL)

PD-1

History / paused

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

AGEN SEC archive